Back

GSK shares rise 4.07% as lung cancer trials show survival benefits

Verifying
  • GSK released positive results from two lung cancer trials involving Ris-Rez and Jideytro.
  • Ris-Rez reduced mortality risk 54% and delivered median overall survival of 18.5 months.
  • GSK plans to submit Jideytro’s supplemental New Drug Application this year.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.